Document is current
Any future updates will be listed below
-
Authors
Huang, Sijie
Liu, Heng https://orcid.org/0000-0001-9195-1191
Wu, Yujin https://orcid.org/0000-0003-2773-9262
Braz, Joao M. https://orcid.org/0000-0002-5792-1017
Kranthi, Divya
Hall, Brendan W. https://orcid.org/0000-0003-1616-1303
Zhang, Xinyue https://orcid.org/0009-0004-3893-9651
Radchenko, Dmytro S. https://orcid.org/0000-0001-5444-7754
Moroz, Yurii S. https://orcid.org/0000-0001-6073-002X
Irwin, John J. https://orcid.org/0000-0002-1195-6417
Basbaum, Allan I. https://orcid.org/0000-0002-1710-6333
Xu, H. Eric https://orcid.org/0000-0002-6829-8144
Wetsel, William C. https://orcid.org/0000-0002-3592-7397
Shoichet, Brian K. https://orcid.org/0000-0002-6098-7367
-
Funding
Funding for this research was provided by:
UCSF Internal Funding and see acknowledgment section--none of the funders listed came up
- License Information
-
More Information
Article History
Received: 9 October 2025
Accepted: 10 August 2026
First Online: 17 September 2026
Ethics
Competing interests: B.K.S. is a co-founder of Epiodyne, BlueDolphin, and Deep Apple Therapeutics, and serves on the science advisory boards for Schrodinger LLC, Vilya Therapeutics, Frontier Discovery Ltd, and on the SRB of Genentech. J.J.I. is a co-founder of BlueDolphin LLC and of Deep Apple Therapeutics. H.E.X. is a founder of Cascade Pharmaceutics. All other authors declare no competing interests.
